Pictet Asset Management Ltd. lessened its position in Hologic, Inc. (NASDAQ:HOLX) by 93.4% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 141,073 shares of the medical equipment provider’s stock after selling 1,981,273 shares during the quarter. Pictet Asset Management Ltd.’s holdings in Hologic were worth $6,774,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC lifted its position in shares of Hologic by 3,466.7% in the second quarter. CWM LLC now owns 535 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 520 shares in the last quarter. SevenBridge Financial Group LLC lifted its position in shares of Hologic by 172.0% in the second quarter. SevenBridge Financial Group LLC now owns 1,205 shares of the medical equipment provider’s stock valued at $58,000 after acquiring an additional 762 shares in the last quarter. Advisory Services Network LLC lifted its position in shares of Hologic by 12.2% in the second quarter. Advisory Services Network LLC now owns 2,028 shares of the medical equipment provider’s stock valued at $97,000 after acquiring an additional 220 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in Hologic by 127.6% during the first quarter. Rockefeller Capital Management L.P. now owns 2,162 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 1,212 shares in the last quarter. Finally, Pearl River Capital LLC purchased a new position in Hologic during the second quarter worth approximately $126,000. Institutional investors and hedge funds own 95.15% of the company’s stock.

In other Hologic news, insider Peter J. Valenti III sold 7,766 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $49.14, for a total transaction of $381,621.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Stephen P. Macmillan sold 194,396 shares of Hologic stock in a transaction on Monday, August 5th. The shares were sold at an average price of $48.77, for a total value of $9,480,692.92. The disclosure for this sale can be found here. 0.90% of the stock is owned by company insiders.

HOLX stock traded down $0.26 during midday trading on Monday, hitting $49.46. 31,914 shares of the company’s stock were exchanged, compared to its average volume of 1,375,661. The business has a 50-day simple moving average of $49.62 and a two-hundred day simple moving average of $47.45. The company has a current ratio of 1.57, a quick ratio of 1.11 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $13.29 billion, a PE ratio of 22.18, a P/E/G ratio of 2.26 and a beta of 0.78. Hologic, Inc. has a 1-year low of $37.47 and a 1-year high of $52.19.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.02. The company had revenue of $852.40 million during the quarter, compared to analysts’ expectations of $836.91 million. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The firm’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.58 earnings per share. As a group, research analysts expect that Hologic, Inc. will post 2.44 EPS for the current fiscal year.

A number of equities analysts recently commented on the company. TheStreet upgraded Hologic from a “c+” rating to a “b” rating in a research report on Wednesday, July 31st. BidaskClub upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Saturday, July 27th. Needham & Company LLC reiterated a “buy” rating and set a $57.00 price objective (up previously from $52.00) on shares of Hologic in a research report on Thursday, August 1st. Stifel Nicolaus lifted their price objective on Hologic from $43.00 to $48.00 and gave the stock a “hold” rating in a research report on Monday, August 5th. Finally, Piper Jaffray Companies lifted their price objective on Hologic from $49.00 to $59.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $50.12.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Diversification

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.